HEALTH● LOW1h ago · Oct 20, 2026, 4:28 PM
Amgen, AstraZeneca report phase 3 results for Tezspire in eosinophilic esophagitis
Seeking Alpha Tech · global
Amgen and AstraZeneca have reported phase 3 trial results for their drug Tezspire in treating eosinophilic esophagitis. This is a development in pharmaceutical research for a medical condition.
GlobeAlert aggregates and classifies open sources; the story above belongs to its publisher. Summaries are machine-generated from the source text.
More in Health
HEALTHBREAKING31m agoBREAKING: FG Confirms Ebola Case In FCTChannels TVHEALTH51m ago200 live roaches and ‘black slime’ found inside Chicago medical center cafeteriaThe Independent WorldHEALTH1h agoVanessa Kerry is the new WHO envoy for health resilience. What's on her to-do list?NPR NewsHEALTH1h agoThe 4 Best Men Scalp Serums for Thicker , Younger - Looking Hairesquire.com · United States